Systematic Financial Management LP Decreases Stock Holdings in AngioDynamics, Inc. $ANGO

Posted by Francis Steltz on Jul 24th, 2026

Systematic Financial Management LP reduced its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) by 2.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,453,701 shares of the medical instruments supplier’s stock after selling 51,163 shares during the quarter. Systematic Financial Management LP owned 5.94% of AngioDynamics worth $27,899,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in ANGO. Farther Finance Advisors LLC grew its holdings in shares of AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares during the period. Kemnay Advisory Services Inc. acquired a new position in AngioDynamics during the fourth quarter worth $27,000. State of Wyoming purchased a new stake in AngioDynamics during the second quarter worth $31,000. Russell Investments Group Ltd. grew its holdings in AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 3,213 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in AngioDynamics by 359.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 4,268 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ANGO shares. Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Canaccord Genuity Group lifted their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. HC Wainwright boosted their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $19.50.

View Our Latest Research Report on ANGO

AngioDynamics Stock Down 2.7%

Shares of NASDAQ:ANGO opened at $13.44 on Friday. The company has a market cap of $555.48 million, a P/E ratio of -15.45 and a beta of 0.34. AngioDynamics, Inc. has a 52 week low of $8.36 and a 52 week high of $15.19. The business has a fifty day simple moving average of $12.47 and a 200-day simple moving average of $11.37.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last released its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The firm had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Sell-side analysts expect that AngioDynamics, Inc. will post -0.27 earnings per share for the current fiscal year.

About AngioDynamics

(Free Report)

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.